¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Help - - Sign up - Phone number 902 888 740

Indexed in:

Index Medicus/MEDLINE, Excerpta Medica/EMBASE, SCOPUS, Science Citation Index Expanded, Journal Citation Reports/Science Edition, IBECS


  • Impact Factor: 1,314(2015)
  • SCImago Journal Rank (SJR):0,28
  • Source Normalized Impact per Paper (SNIP):0,383
doi: 10.1016/S1575-0922(05)74800-2
Inhibidores de la absorción del colesterol
Cholesterol absorption inhibitors
E. Boix, , A.M. Picó
Sección de Endocrinología y Nutrición. Hospital General Universitario de Alicante. Alicante. España
Received 29 July 2004, Accepted 14 March 2005

La hipercolesterolemia es un factor de riesgo cardiovascular. La reducción eficaz y a largo plazo de las concentraciones de colesterol total y ligado a lipoproteínas de baja densidad previene la mortalidad por enfermedad coronaria. Hasta la fecha los fármacos más eficaces para reducir las concentraciones plasmáticas de colesterol eran los inhibidores de la hidroximetilglutaril coenzima A reductasa (estatinas). Sin embargo, en muchos pacientes la monoterapia con estos fármacos no consigue la reducción del colesterol hasta las cifras establecidas por las guías de actuación clínica, por lo que se hace necesario el tratamiento combinado con otros hipolipemiantes. En el presente artículo se revisan los fármacos que actúan fundamentalmente a través de una inhibición de la absorción del colesterol y su utilidad en la práctica clínica.


Hypercholesterolemia is a cardiovascular risk factor. Effective and long-term reduction of total and low-density lipoprotein cholesterol concentrations lowers mortality from coronary heart disease. Until now the most effective cholesterol-lowering drugs have been hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins). However many patients do not achieve standard treatment goals as defined by clinical guidelines with statins in monotherapy and require combination therapy with other lipid lowering drugs. The present review discusses the pharmacologic agents that act through inhibition of cholesterol absorption and their role in the clinical management of hypercholesterolemia.

Palabras clave
Colesterol, Absorción intestinal, Ezetimiba
Key words
Cholesterol, Intestinal absorption, Ezitimibe
This article is only available in PDF
J. Stamler,D. Wentworth,J.D. Neaton
Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA, 256 (1986), pp. 2823-2828
M.R. Law,N.J. Wald,S.G. Thompson
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
BMJ, 308 (1994), pp. 367-372
M.R. Law,N.J. Wald
An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990
Eur J Clin Nutr, 48 (1994), pp. 305-325
J. Stamler,M.L. Daviglus,D.B. Garside,A.R. Dyer,P. Greenland,J.D. Neaton
Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
JAMA, 284 (2000), pp. 311-318
M.R. Law,N.J. Wald,A.R. Rudnicka
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
BMJ, 326 (2003), pp. 1423
Scandinavian Simvastatin Survival Study Group
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lancet, 344 (1994), pp. 1383-1389
West of Scotland Coronary Prevention Study Group
Influence of pravastatin and plasma levels on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
Circulation, 97 (1998), pp. 1440-1445
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
N Engl J Med, 339 (1998), pp. 1349-1357
J.R. Downs,M. Clearfield,S. Weis,E. Whytney,D.R. Shapiro,P.A. Beere
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS
JAMA, 279 (1998), pp. 1615-1622
F.M. Sacks,L.A. Moyé,B.R. Davis,T.G. Cole,J.L. Rouleau,D.T. Nash
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial
Circulation, (1998), pp. 97
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
T.A. Pearson,I. Laurora,H. Chu,S. Kafonek
The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
Arch Intern Med, 160 (2000), pp. 459-467
T.C. Andrews,C.M. Ballantyne,J.A. Hsia,J.H. Kramer
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins
Am J Med, 111 (2001), pp. 185-191
P. Jones,S. Kafonek,I. Laurora,D. Hunninghake
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Am J Cardiol, 81 (1998), pp. 582-587
G.R. Thompson,F. O’Neill,M. Seed
Why some patients respond poorly to statins and how this might be remedied
Eur Heart J, 23 (2002), pp. 200-206
Heart Protection Study Collaborative Group
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
Lancet, 360 (2002), pp. 7-22
P.S. Sever,B. Dahlof,N.R. Poulter,H. Wedel,G. Beevers,M. Caulfield
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Lancet, 361 (2003), pp. 1149-1158
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
JAMA, 288 (2002), pp. 2998-3007
C.P. Cannon,E. Braunwald,C.H. McCabe,D.J. Rader,J.L. Rouleau,R. Belder,Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 Investigators
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N Engl J Med, 350 (2004), pp. 1495-1504
S.M. Grundy,J.I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,L.T. Clark,D.B. Hunninghake
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Circulation, 13 (2004), pp. 227-239
S.M. Bosner,L.G. Lange,W.F. Stenson,R.E. Ostlund Jr
Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectometry
J Lipid Res, 40 (1999), pp. 302-308
Q.H. David,M.D. Wang
New concepts of mechanisms of intestinal cholesterol absorption
Ann Hepatol, 2 (2003), pp. 113-121
E. Ros
Inhibición de la absorción intestinal del colesterol: nueva diana terapéutica en la reducción de la colesterolemia
Clin Invest Arterioscl, 15 (2003), pp. 261-275
H. Thurnhofer,H. Hauser
Uptake of cholesterol by small intestinal brush border membrane is protein-mediated
Biochemistry, 29 (1990), pp. 2142-2148
S. Compassi,M. Werder,D. Boffelli,F.E. Weber,H. Hauser,G. Schulthess
Cholesteryl ester absorption by small intestinal brush border membrane is protein-mediated
Biochemistry, 34 (1995), pp. 16473-16482
R.A. Moreau,B.D. Whitaker,K.B. Hicks
Phytosterols, phytostanols, and their conjugates in foods: structural diversity, quantitative analysis, and health-promoting uses
Prog Lipid Res, 41 (2002), pp. 457-500
V. Piironen,D.G. Lindsay,T.A. Miettinen,J. Toivo,A.M. Lampi
Plant sterols: biosynthesis, biological function and their importance to human nutrition
J Sci Food Agric, 80 (2000), pp. 939-966
G. Schmitz,T. Langmann,S. Helmerl
Role of ABCG1 and other ABCG family members in lipid metabolism
J Lipid Res, 42 (2001), pp. 1513-1520
K.E. Berge,H. Tian,G.A. Graf,L. Yu,N.V. Grishin,J. Schultz
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters
Science, 290 (2000), pp. 1771-1775
M.H. Lee,K. Lu,S. Hazard,H. Yu,S. Shulenin,K. Hidaka
Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption
Nat Genet, 27 (2001), pp. 79-83
L. Yu,R.E. Hammer,J. Li-Hawkins,K. Von Bergmann,D. Lutjohann,J.C. Cohen
Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion
Proc Natl Acad Sci USA, 99 (2002), pp. 16237-16242
L. Yu,J. Li-Hawkins,R.E. Hammer,K.E. Berge,J.D. Horton,J.C. Cohen
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol
J Clin Invest, 110 (2002), pp. 671-680
L. Yu,J. York,K. Von Bergmann,D. Lutjohann,J.C. Cohen,H.H. Hobbs
Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8
J Biol Chem, 278 (2003), pp. 15565-15570
G.A. Graf,W.P. Li,R.D. Gerard,I. Gelissen,A. White,J.C. Cohen
Coexpression of ATP-binding cassette proteins ABCG5 y ABCG8 permits their transport to the apical surface
J Clin Invest, 110 (2002), pp. 659-669
L.-P. Duan,D.-H. Wang
Sterols influence intestinal cholesterol absorption through mediating expression of the ileal ATP-binding cassette transporters G5 and G8 (ABCG5/G8)
Gastroenterology, 122 (2002), pp. A403
V.M. Morales,D.-H. Wang
Expression of intestinal ATP-binding cassette transporters G5 and G8 (ABCG5/G8) plays a major role in determining variations in cholesterol absorption efficiency in inbred mice
Gastroenterology, 122 (2002), pp. A58
C. Joyce,K. Skinner,R.A. Anderson,L.L. Rudel
Acyl-coenzyme A: cholesterol acyltransferase 2
Curr Opin Lipidol, 10 (1999), pp. 89-95
D.A. Gordon
Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly
Curr Opin Lipidol, 8 (1997), pp. 131-137
Lipid Research Clinics Program
The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease
JAMA, 251 (1984), pp. 351-364
Lipid Research Clinics Program
The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
JAMA, (1984), pp. 251
Pravastatin Multicenter Study Group II
Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
Arch Intern Med, 153 (1993), pp. 1321-1329
V. Piironen,J. Toivo,A.M. Lampi
Natural sources of dietary plant sterols
J Food Comp Anal, 13 (2000), pp. 619-624
K.M. Phillips,D.M. Ruggio,J.I. Toivo,M.A. Swank,A.H. Simpkins
Free and esterified sterol composition of edible oils and fats
J Food Comp Anal, 15 (2002), pp. 123-142
T. Heinemann,G. Axtmann,K. Von Bergmann
Comparison of intestinal absorption of cholesterol with different plant sterols in man
Eur J Clin Invest, 23 (1993), pp. 827-831
R.E. Ostlund Jr,J.B. McGill,C.M. Zeng,D.F. Covey,J. Stearns,W.F. Stenson
Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans
Am J Physiol Endocrinol Metab, 282 (2002), pp. E911-E916
P.V. Koivisto,T.A. Miettinen
Plasma and biliary cholestanol related to steroid metabolism in familial hypercholesterolemia patients with and without ileal exclusion
Clin Chim Acta, 174 (1988), pp. 197-205
O. Pollak
Reduction of blood cholesterol in man
Circulation, 7 (1953), pp. 702-706
H. Gylling,T.A. Miettinen
LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects
Nutr Metab Cardiovasc Dis, 12 (2002), pp. 19-23
E.H.M. Temme,P.G.A. Van Hoydonck,E.G. Schouten,H. Kesteloot
Effects of a plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolaemic subjects
Acta Cardiol, 57 (2002), pp. 111-115
J. De Graaf,P.R. De Sauvage Nolting,M. Van Dam,E.M. Belsey,J.J. Kastelein,P. Haydn Pritchard
Consumption of tall-oil derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels
Br J Nutr, 88 (2002), pp. 479-488
C.A. Vanstone,M. Raeini-Sarjaz,W.E. Parsons,P.J. Jones
Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons
Am J Clin Nutr, 76 (2002), pp. 1272-1278
O.A. Matvienko,D.S. Lewis,M. Swanson,B. Arndt,D.L. Rainwater,J. Stewart
A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men
Am J Clin Nutr, 76 (2002), pp. 57-64
M.J. Mussner,K.G. Parhofer,K. Von Bergmann,P. Schwandt,U. Broedl,C. Otto
Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake
Metabolism, 51 (2002), pp. 189-194
J.T. Judd,D.J. Baer,S.C. Chen,B.A. Clevidence,R.A. Muesing,M. Kramer
Plant sterol esters lower plasma lipids and most carotenoids in mildly hypercholesterolemic adults
Lipids, 37 (2002), pp. 33-42
R.P. Mensink,S. Ebbing,M. Lindhout,J. Plat,M.M. Van Heugten
Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations
Atherosclerosis, 160 (2002), pp. 205-213
A.L. Amundsen,L. Ose,M.S. Nenseter,F.Y. Ntanios
Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia
Am J Clin Nutr, 76 (2002), pp. 338-344
M. Raeini-Sarjaz,F.Y. Ntanios,C.A. Vanstone,P.J.H. Jones
No changes in serum fat-soluble vitamin and carotenoid concentrations with the intake of plant sterol/stanol esters in the context of a controlled diet
Metabolism, 51 (2002), pp. 652-656
M. Noakes,P. Clifton,F. Ntanios,W. Shrapnel,I. Record,J. Mc-Inerney
An increase in dietary carotenoids when consuming plant sterols or stanols is effective in maintaining plasma carotenoid concentrations
Am J Clin Nutr, 75 (2002), pp. 79-86
M.J. Tikkanen,P. Hogstrom,J. Tuomilehto,S. Keinanen-Kiukaanniemi,J. Sundvall,H. Karppanen
Effect of a diet based on low-fat foods enriched with nonesterified plant sterols and mineral nutrients on serum cholesterol
Am J Cardiol, 88 (2001), pp. 1157-1162
R. Volpe,L. Niittynen,R. Korpela,C. Sirtori,A. Bucci,N. Fraone
Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia
Br J Nutr, 86 (2001), pp. 233-239
H.A.W. Neil,G.W. Meijer,L.S. Roe
Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread
Atherosclerosis, 156 (2001), pp. 329-337
P. Nestel,M. Cehun,S. Pomeroy,M. Abbey,G. Weldon
Cholesterol-lowering effects of plant sterol esters and non-esterified stanols in margarine, butter and low-fat foods
Eur J Clin Nutr, 55 (2001), pp. 1084-1090
J.C. Russell,H.S. Ewart,S.E. Kelly,J. Kralovec,J.L.C. Wright,P.J. Dolphin
Improvement of vascular disfunction and blood lipids of insulin resistant rats by a marine oil-based phytosterol compound
Lipids, 37 (2002), pp. 147-152
H.S. Ewart,L.K. Cole,J. Kralovec,H. Layton,J.M. Curtis,J.L.C. Wright
Fish oil containing phytosterol esters alters blood lipid profiles and left ventricle generation of thromboxane A2 in adult guinea pigs
J Nutr, 132 (2002), pp. 1149-1152
J. Quílez,P. García-Lorda,J. Salas-Salvadó
Potential uses and benefits of phytosterols in diet: present situation and future directions
Clin Nutr, 22 (2003), pp. 343-351
H.F.J. Hendriks,J.A. Weststrate,T. Van Vliet,G.W. Meijer
Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects
Eur J Clin Nutr, 53 (1999), pp. 319-327
J.A. Weststrate,G.W. Meijer
Plant sterol-enriched margarines and reduction of plasma total and LDL-cholesterol concentration in normocholesterolaemic and mildly hypercholesterolaemic subjects
Eur J Clin Nutr, 52 (1998), pp. 334-343
K.E. Suckling,E.F. Stange
Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism
J Lipid Res, 26 (1985), pp. 647-671
T. Sudhop,K. Von Bergmann
Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia
Drugs, 62 (2002), pp. 2333-2347
W.Jr Insull,M. Koren,J. Davignon,D. Sprecher,H. Schrott,L.M. Keilson
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia
Atherosclerosis, 157 (2001), pp. 137-144
F.J. Raal,A.D. Marais,E. Klepack,J. Lovalvo,R. McLain,T. Heinonen
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia
Atherosclerosis, 171 (2003), pp. 273-279
J.C. Tardif,J. Gregoire,J. Lesperance,J. Lambert,P.L. L’Allier,J. Rodes
Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular Ultra-Sound (A-PLUS) clinical trial
Am Heart J, 144 (2002), pp. 589-596
R.E. Gregg,J.R. Wetterau
The molecular basis of abetalipoproteinemia
Curr Opin Lipidol, 5 (1994), pp. 81-86
J.R. Wetterau,R.E. Gregg,T.W. Harrity,C. Arbeeny,M. Cap,F. Connolly
An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
Science, 282 (1998), pp. 751-754
M. Farnier,E. Stein,S. Megnien
Efficacy and safety of implitapide, a microsomal triglyceride transfer protein inhibitor in patients with primary hypercholesterolemia
XIV International Symposium on Drugs Affecting Lipid Metabolism,
K. Von Bergmann,G. Salen,D. Lutjohann,T. Musliner,B. Musser
Ezetimibae efectively reduces serum plant sterols in patients with sitosterolemia
Atherosclerosis Suppl, 3 (2002), pp. 232
F. Ezzet,G. Krishna,D.B. Wexler,P. Statkevich,T. Kosoglou,V.K. Batra
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimiba
Clin Ther, 23 (2001), pp. 871-885
H.E. Bays,P.B. Moore,M.A. Drehobl,S. Rosenblatt,P.D. Toth,C.A. Dujovne
Effectiveness and tolerability of ezetimibain patients with primary hypercholesterolemia: pooled analysis of two phase II studies
Clin Ther, 23 (2001), pp. 1209-1230
A. Zacs,D.R. Dodds
Enzymatic glucuronidation of a novel cholesterol absorption inhibitor SCH 58235
Appl Biochem Biotechnol, 73 (1998), pp. 205-214
M. Harris,W. Davis,W.V. Brown
Drugs Today (Barc), 39 (2003), pp. 229-247
G.D. Norata,A.L. Catapano
Lipid lowering activity of drugs affecting cholesterol absorption
Nutr Metab Cardiovasc Dis, 14 (2004), pp. 42-51
M. Van Heek,C. Farley,D.S. Compton,L. Hoos,K.B. Alton,E.J. Sybertz
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
Br J Pharmacol, 129 (2000), pp. 1748-1754
C. Simard,J. Turgeon
The pharmacokinetics of ezetimiba
Can J Clin Pharmacol, 10 (2003), pp. 13A-20A
K.S. Bauer,T. Kosoglou,P. Statkevich,A. Calzetta,S.E. Maxwell,J.E. Patrick
Ezetimiba does not affect the pharmacokinetics or pharmacodynamics of warfarin
Clin Pharmacol Ther, 69 (2001), pp. P5
A.C. Keung,T. Kosoglou,P. Statkevich,L. Anderson,T. Boutros,D.L. Cutler
Ezetimiba does not affect the pharmacokinetics of oral contraceptives
Clin Pharmacol Ther, 69 (2001), pp. P55
T. Kosoglou,P. Statkevich,L. Reyderman,L.J.C. Pember,S.E. Maxwell,R. Courtney
Effects of selected drugs on exposure to ezetimiba [abstract]
Eur Heart J, 24 (2003), pp. 462
T. Kosoglou,P. Statkevich,K.S. Bauer
Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of digoxin
AAPS Pharm Sci, (2001), pp. 3
P. Statkevich,L. Reyderman,T. Kosoglou,M. Woloj,S.E. Maxwell,D.L. Cutler
Ezetimiba does not affect the pharmacokinetics and pharmacodynamics of glipizide
Clin Pharmacol Ther, 69 (2001), pp. P67
L. Reyderman,T. Kosoglou,P. Statkevich,L. Anderson,T. Boutros,V. Batra
No pharmacokinetic drug interaction between ezetimiba and lovastatin
Clin Pharmacol Ther, 69 (2001), pp. P66
T. Kosoglou,I. Meyer,E.P. Veltri,P. Statkevich,B. Yang,Y. Zhu
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimiba and simvastatin
Br J Clin Pharmacol, 54 (2002), pp. 309-319
T. Kosoglou,M. Seiberling,P. Statkevich,D.L. Cutler,B. Yang,L. Anderson
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimiba and atorvastatin
J Am Coll Cardiol, 37 (2001), pp. 229A
Y. Zhu,P. Statkevich,T. Kosoglou,S.E. Maxwell,L. Anderson,J.E. Patrick
Lack of pharmacokinetic interaction between ezetimibaand atorvastatin
Clin Pharmacol Ther, 69 (2001), pp. P68
L. Reyderman,T. Kosoglou,P. Statkevich,L. Pember,S. Maxwell,V. Batra
Pharmacokinetics of ezetimibain subjects with normal renal function or severe chronic renal insufficiency
Clin Pharmacol Ther, 71 (2002), pp. P27
R.H. Knopp,H. Bays,C.V. Manion,L.J. Lipka,L. Melani,A.P. LeBeaut
Effect of ezetimiba on serum concentrations of lipid-soluble vitamins
Atherosclerosis, 2 (2001), pp. 90
T. Sudhop,D. Lutjohann,A. Kodal,M. Igel,D.L. Tribble,S. Shah
Inhibition of intestinal cholesterol absorption by ezetimiba in humans
Circulation, 106 (2002), pp. 1943-1948
C.A. Dujovne,M.P. Ettinger,J.F. McNeer,L.J. Lipka,A.P. LeBeaut,R. Suresh
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimiba, in patients with primary hypercholesterolemia
Am J Cardiol, 90 (2002), pp. 1092-1097
R.H. Knopp,H. Gitter,T. Truitt,H. Bays,C.V. Manion,L.J. Lipka
Effects of ezetimiba, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia
Eur Heart J, 24 (2003), pp. 729-741
C. Gagne,H.E. Bays,S.R. Weiss,P. Mata,K. Quinto,M. Melino
Efficacy and safety of ezetimiba added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
Am J Cardiol, 90 (2002), pp. 1084-1091
M.H. Davidson,T. McGarry,R. Bettis,L. Melani,L.J. Lipka,A.P. Le-Beaut
Ezetimiba coadministered with simvastatin in patients with primary hypercholesterolemia
J Am Coll Cardiol, 40 (2002), pp. 2125-2134
C.M. Ballantyne,J. Houri,A. Notarbartolo,L. Melani,L.J. Lipka,R. Suresh
Effect of ezetimiba coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Circulation, 107 (2003), pp. 2409-2415
L. Melani,R. Mills,D. Hassman,R. Lipetz,L. Lipka,A. LeBeaut
Efficacy and safety of ezetimiba coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Eur Heart J, 24 (2003), pp. 717-728
B. Kerzner,J. Corbelli,S. Sharp,L.J. Lipka,L. Melani,A. LeBeaut
Efficacy and safety of ezetimiba coadministered with lovastatin in primary hypercholesterolemia
Am J Cardiol, 91 (2003), pp. 418-424
L. Lipka,L. Melani,A. LeBeaut,S. Sun,R. Suresh,E.E.S.G. Veltri
Consistency of LDL-C lowering effect across subgroups of ezetimiba co-administered with statins
Eur Heart J, 23 (2002), pp. 19
T. Kosoglou,M. Guillaume,S. Sun
Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe
Atherosclerosis, (2001), pp. 2
Correspondencia: Dra. E. Boix Carreño. Partida de Alzabares Alto. Polígono 1. 146-147-A. 03290 Elche. Alicante. España.
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición